Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma - Takeaways - MDSpire

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma

  • By

  • Meletios A. Dimopoulos

  • Sagar Lonial

  • Wee-Joo Chng

  • Shinsuke Iida

  • María-Victoria Mateos

  • Gareth J. Morgan

  • Cong Li

  • Catriona Byrne

  • Kaveri Suryanarayan

  • Richard Labotka

  • S. Vincent Rajkumar

  • December 4, 2025

  • 0 min

Share

  • 1

    Ixazomib is an oral proteasome inhibitor approved for maintenance therapy in newly diagnosed multiple myeloma after primary therapy.

  • 2

    The TOURMALINE-MM3 and MM4 studies showed significant improvements in progression-free survival with ixazomib compared to placebo.

  • 3

    Overall survival analyses for both studies did not show statistically significant differences between ixazomib and placebo.

  • 4

    Sensitivity analyses suggested a potential trend favoring ixazomib in overall survival, but results were not statistically significant.

  • 5

    The evolving treatment landscape in multiple myeloma challenges the relevance of overall survival as a key endpoint in clinical trials.

Original Source(s)

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma

  • by Meletios A. Dimopoulos, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, María-Victoria Mateos, Gareth J. Morgan, Cong Li, Catriona Byrne, Kaveri Suryanarayan, Richard Labotka, S. Vincent Rajkumar

  • December 4, 2025

Related Content

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

Understanding the Role of Regulatory T Cells in the Immune Microenvironment of Multiple Myeloma and Its Clinical Implications